Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from primary mouse blood stem cells. Phase I of this project included applying this technology to generate human cell lines. In addition, the project included testing a non-viral method to generate the stem cell lines from mice. Phase II of the project will entail optimizing large-scale production of protein transduced long-term hematopoietic stem cells from human cells that are resistant to HIV infection for eventual testing in larger animals and human clinical trials.

Public Health Relevance

This project seeks to optimize a novel method to generate large amounts of human blood stem cells for clinical use in the prevention and treatment of HIV infection. Once this method has been validated for large-scale production, the long-term goal for benefiting public health will be to use this system to generate HIV resistant cells in infected individuals or in populations that are at-risk for acquiring the HIV virus.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL091740-03
Application #
8111916
Study Section
Special Emphasis Panel (ZRG1-AARR-E (11))
Program Officer
Mitchell, Phyllis
Project Start
2008-09-19
Project End
2013-01-31
Budget Start
2011-08-01
Budget End
2013-01-31
Support Year
3
Fiscal Year
2011
Total Cost
$759,221
Indirect Cost
Name
Taiga Biotechnologies, Inc.
Department
Type
DUNS #
783743938
City
Aurora
State
CO
Country
United States
Zip Code
80045